These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35144855)

  • 1. Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Mannucci E; Giaccari A; Gallo M; Targher G; Pintaudi B; Candido R; Monami M;
    Nutr Metab Cardiovasc Dis; 2022 Mar; 32(3):529-536. PubMed ID: 35144855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of insulin on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Mannucci E; Targher G; Nreu B; Pintaudi B; Candido R; Giaccari A; Gallo M; Monami M;
    Nutr Metab Cardiovasc Dis; 2022 Jun; 32(6):1353-1360. PubMed ID: 35422359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials.
    Mannucci E; Monami M; Candido R; Pintaudi B; Targher G;
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1601-1608. PubMed ID: 32811736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials.
    Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
    Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):699-704. PubMed ID: 33549430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events.
    Mannucci E; Gallo M; Giaccari A; Candido R; Pintaudi B; Targher G; Monami M;
    Diabetes Obes Metab; 2023 Feb; 25(2):444-453. PubMed ID: 36205446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials.
    Mannucci E; Gallo M; Pintaudi B; Targher G; Candido R; Giaccari A; Monami M;
    Nutr Metab Cardiovasc Dis; 2022 Feb; 32(2):511-514. PubMed ID: 34893404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials.
    Sinha B; Ghosal S
    Sci Rep; 2020 Sep; 10(1):15781. PubMed ID: 32978507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.
    Zhou Y; Huang Y; Ji X; Wang X; Shen L; Wang Y
    J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 31822895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.
    Mannucci E; Nreu B; Montereggi C; Ragghianti B; Gallo M; Giaccari A; Monami M;
    Nutr Metab Cardiovasc Dis; 2021 Sep; 31(10):2745-2755. PubMed ID: 34364771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
    Liao HW; Saver JL; Wu YL; Chen TH; Lee M; Ovbiagele B
    BMJ Open; 2017 Jan; 7(1):e013927. PubMed ID: 28057658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
    Monami M; Dicembrini I; Mannucci E
    Acta Diabetol; 2017 Jan; 54(1):19-36. PubMed ID: 27488726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
    Lincoff AM; Wolski K; Nicholls SJ; Nissen SE
    JAMA; 2007 Sep; 298(10):1180-8. PubMed ID: 17848652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.
    de Jong M; van der Worp HB; van der Graaf Y; Visseren FLJ; Westerink J
    Cardiovasc Diabetol; 2017 Oct; 16(1):134. PubMed ID: 29037211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Lamanna C; Gensini GF; Marchionni N
    Diabetes Obes Metab; 2008 Dec; 10(12):1221-38. PubMed ID: 18505403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.